Heart rate variability and clinical cardiology
The first observation that heart rate variability (HRV) could be used as a predictor of mortality after acute myocardial infarction was published in 1978.' Since then the usefulness of HRV for the identification of patients at high risk after acute infarction has been confirmed in large studies. 23 Not surprisingly, these discoveries led to widespread interest in HRV among clinical investigators and until now HRV has been not only the subject of many physiologically oriented investigations but also its potential practical value has been assessed in patients from many different clinical groups.
There are important differences between the type of heart rhythm recordings used for purely physiological studies and those used for fully clinical studies. Whereas the physiologist tends to obtain recordings of heart rhythm under strictly controlled conditions, the clinician generally uses standard ambulatory electrocardiograms, and data from these are much less stationary. In clinical recordings the different processes modulating the heart rate are much less easily distinguishable.
The editorial by Malliani et al on page 1 of this issue4 describes the state-of-the-art of the physiological background of HRV. We will discuss contemporary experience with and understanding of the clinical use of HRV. Although assessment of HRV is of indisputable value in many non-cardiological clinical disciplines-for example, neurology,5 diabetology,6 obstetrics,7 occupational medicine8-we will concentrate solely on the potential use of HRV in clinical cardiology.
Cardiac failure HRV is depressed in patients with heart failure. However, these patients have faster heart rates, owing to the predominance of sympathetic tone, which partly accounts for the depression of HRV. In addition, maintaining a minimum diastolic interval9 tends to reduce the variation of heart periods even more in patients in heart failure. Several studies have been conducted to investigate the sympathetic and parasympathetic components of HRV in heart failure. Coumel et al investigated the effects of medium-term / blockade and found that heart rate was significantly more depressed in patients with heart failure rate than in healthy controls.'0 They also found a specific decrease in the sympathetic components of HRV in heart failure. ' 13 In their study only the measures of ultra-low frequencies of HRV were correlated with left and right ventricular ejection fraction and these measures of HRV were most predictive of mortality, disease progression, and development of atrial fibrillation.
All spectral components of HRV have repeatedly been observed to be depressed in patients with heart failure but the pathophysiological mechanism remains unclear. At present the assessment of HRV is of no practical value in the management of patients with heart failure.
Heart transplantation A recently transplanted heart has no innervation. Therefore the heart transplant recipient exhibits reduced HRV. Sands et al observed not only a reduced total spectral power of HRV in these patients but also power spectra of HRV without any distinct peaks.'4 They also found that the total spectral power of HRV was increased in those patients with transplants in whom allograft rejection developed but not in those whose endomyocardial biopsy specimens showed no evidence of rejection. In patients with rejection, however, HRV was increased by overall chaotic irregularities of the cardiac rhythm without noticeable periodic components.
Bernardi et al observed depressed HRV at rest in patients with transplants but found direct correlation between the high frequency components of HRV and respiration rate during exercise."' This suggests that a non-autonomic nervous mechanism, possibly humoral or intrinsic to the myocardium but masked by autonomic effects in non-transplanted hearts, influences HRV at peak exercise in synchrony with ventilation. Smith et al studied HRV changes caused by reinnervation of the transplanted heart.'6 They reported that parasympathetic components of HRV do not rise during the first month after transplantation but increase significantly between 3 and 6 months, suggesting early reinnervation of the parasympathetic system.
Thus the reduction of total values of HRV as well as the disappearance of its distinct spectral peaks in cardiac transplant recipients is well established. The observation that a white-noise-like increase of HRV might be a warning sign of allograft rejection needs further confirmation. Reinnervation is likely to be detected by the reappearance of physiological spectra rather than by an increase in the total power of HRV in transplanted patients.
Essential hypertension
Guzetti et al studied the effect on HRV of enhanced sympathetic activity in patients with essential hypertension.-Compared with normotensive controls the low frequency components of HRV were larger in hypertensive patients and the high frequency components were smaller. A passive tilt produced smaller changes in the relation between the high and low frequency components of HRV in hypertensive patients than in controls. Moreover, both the values of low frequency components and the extent of the altered effects of tilt on HRV components strongly correlated with the degree of hypertension. Chronic fi adrenergic blockade which reduced blood pressure in hypertensive patients also changed the HRV components towards normal values. Thus measurement of HRV might assess progressive alterations in the sympathovagal balance observed in essential hypertension. No study, however, has so far demonstrated a strong correlation between HRV variables and cardiac arrhythmias or the risk of sudden death in essential hypertension.
Risk stratification after myocardial infarction
The most updated use of HRV is for risk stratification after myocardial infarction. Wolf et al first reported that patients with acute myocardial infarction who lack respiratory sinus arrhythmia have a significantly higher risk of in-hospital mortality.' Later, this observation was confirmed for the post-discharge phase by several centres using independent data. Other recent studies have reproduced the original findings of Wolf et al and, in addition, have shown that HRV assessed during the acute phase of myocardial infarction is significantly related to clinical and haemodynamic indices of severity, such as peak creatine kinase, left ventricular ejection fraction, and Killip class. '8 Compelling evidence that HRV is a powerful risk predictor after myocardial infarction first came from the investigators of the Multicenter Post-Infarction Research Group. In their report, Kleiger et al showed a strong association between depressed HRV and increased mortality during the first four years after acute infarction.2 By clustering the total population according to mean heart rate, left ventricular ejection fraction, frequency of ventricular extrasystoles, and presence of couplets or runs of ventricular extrasystoles Kleiger et al showed that depressed HRV predicted mortality independently of these recognised risk factors. In a subsequent study that 
Whether reduced HRV in high risk survivors of infarction is the result of generally decreased autonomic tone or whether it is the consequence of diminished cardiac response to autonomic stimuli remains to be elucidated. Nevertheless, animal models have shown that the change in cardiac autonomic tone that makes the heart of some animals more susceptible to ventricular fibrillation occurs in close relation to the experimental infarction. Hull et al investigated HRV in dogs before and 1 month after experimental myocardial infarction.2' They did not find any difference in HRV assessed before infarction between those animals that survived 1 month and those that died suddenly during this period. They also observed that depression of HRV was much greater in those animals in which ventricular fibrillation developed during exercise and ischaemia.
Does the prognostic power of a post-infarction HRV value assessed from a short-term recording equal that measured from 24 hour electrocardiograms? Malik et al found that arbitrary short-term recordings are not sufficient because their specificity for predicting arrhythmia risk is small.24 Only when the total circadian variation of autonomic nervous activity was integrated did practically acceptable values of sensitivity and specificity emerge. However, we do not know the predictive power of HRV assessed from short-term recordings made under strict conditions-for example, controlled respiration. Several physiological studies have investigated such short-term recordings but the patient population has never been large enough to assess their predictive power. The observations made with arbitrary short-term recordings accord with a study by Bigger et al who compared the predictive power of different spectral components of HRV for the identification of the risk of post-infarction mortality.25 They found the highest predictive power in the ultra-low frequency components corresponding to heart rate oscillations in terms of hours rather than minutes.
These Odemuyiwa et al investigated whether post-infarction HRV is more powerful as a predictor of total cardiac mortality, of arrhythmic complications (that is, sudden deaths and sustained symptomatic ventricular tachycardia), or of sudden death alone.' When the predictive powers of decreased HRV and decreased left ventricular ejection fraction were compared HRV was found to be about as powerful as the ejection fraction for predicting total cardiac mortality in the post-infarction population whereas it was significantly more powerful than the ejection fraction for predicting sudden death and symptomatic ventricular tachycardia. This finding accords with our understanding of the pathophysiology of depressed HRV after myocardial infarction. The reduced left ventricular ejection fraction is more likely to reflect a liability to cardiac failure and thus to identify patients who are at risk of non-sudden death, some of whom will also develop ventricular fibrillation and die suddenly. On the contrary, reduced HRV reflects the lack of an autonomic defence against ventricular fibrillation and thus more powerfully identifies those patients who are at high risk of sudden death or arrhythmic complications.
Investigations Surgically excised papillary fibroelastoma.
